Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RECAST: FOLFIRI + ramucirumab versus FOLFOXIRI + ramucirumab in first-line metastatic colorectal cancer
jRCTs041180166Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of ramucirumab in metastatic colon cancer (mCRC) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Objective response rate. Started Jun 2017; status: completed.
02
Drugs
ramucirumab
03
Conditions
metastatic colon cancer (mCRC)
Beyond the preview
Go deeper on jRCTs041180166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041180166.